Clinical Trial Update: Phase 1 Study Of Intrathecal Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells For Patients With Leptomeningeal Melanoma [Phase 1]

View source ↗

Summary

Phase 1 intrathecal adoptive immunotherapy using autologous CD8+ antigen-specific T cells for leptomeningeal melanoma is in early-stage development. The study s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Melanoma

Drugs mentioned

• Autologous CD8+ antigen-specific T cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leptomeningeal Melanoma | Phase 1 | Status: NOT_YET_RECRUITING